CC-401

• Description :

  CC-401 is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  JNK

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cc-401.html

• Purity :

  99.63

• Solubility :

  DMSO : 40 mg/mL (ultrasonic)

• Smiles :

  C1(C2=CC=CC(OCCN3CCCCC3)=C2)=NNC4=C1C=C(C=C4)C5=NC=NN5

• Molecular Formula :

  C22H24N6O

• Molecular Weight :

  388.47

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ma FY, et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol. 2007 Feb;18 (2) :472-84.|[2]Vasilevskaya IA, et al. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents. Clin Cancer Res. 2015 Sep 15;21 (18) :4143-52.|[3]Ma FY, et al. Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest. 2009 Apr;89 (4) :470-84.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  JNK

• Citation 01 :

  Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|Mol Cancer Res. 2016 Aug;14 (8) :753-63.|Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2024 Dec 9:145:113781.|Science. 2017 Dec 1;358 (6367) :eaan4368.

• CAS Number :

  [395104-30-0]